Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …

M Sholzberg, GH Tang, H Rahhal, M AlHamzah… - bmj, 2021 - bmj.com
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Randomized trials of therapeutic heparin for COVID‐19: a meta‐analysis

M Sholzberg, BR da Costa, GH Tang… - … and practice in …, 2021 - Wiley Online Library
Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute
to hypoxemic respiratory failure, the most common cause of death, in patients with COVID …

Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …

AC Spyropoulos, M Goldin, D Giannis… - JAMA internal …, 2021 - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study

A Di Castelnuovo, S Costanzo… - Thrombosis and …, 2021 - thieme-connect.com
Introduction A hypercoagulable condition was described in patients with coronavirus
disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing …

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 …

M Marietta, P Vandelli, P Mighali, R Vicini, V Coluccio… - Trials, 2020 - Springer
Objectives To assess whether high doses of Low Molecular Weight Heparin (LMWH)(ie
Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin …

Preliminary experience with low molecular weight heparin strategy in COVID-19 patients

P Paolisso, L Bergamaschi, EC D'Angelo… - Frontiers in …, 2020 - frontiersin.org
Background Heparin administration in COVID-19 patients is recommended by expert
consensus, although evidence about dosage, duration and efficacy are limited. We aim to …

The association between treatment with heparin and survival in patients with Covid-19

L Ayerbe, C Risco, S Ayis - Journal of thrombosis and thrombolysis, 2020 - Springer
This study investigates the association between the treatment with heparin and mortality in
patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April …

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre …

F Cools, S Virdone, J Sawhney, RD Lopes… - The Lancet …, 2022 - thelancet.com
Background COVID-19 is associated with inflammation and an increased risk of
thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have …

Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19

EC Goligher, PR Lawler, TP Jensen, V Talisa, LR Berry… - Jama, 2023 - jamanetwork.com
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients
hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of …

Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19

I Martinelli, A Ciavarella, M Abbattista, S Aliberti… - Internal and emergency …, 2021 - Springer
We conducted an observational cohort study in adult patients consecutively admitted for the
respiratory illness Covid-19 to our hub hospital from March 9 to April 7, 2020. The high …